Page last updated: 2024-10-22

altretamine and Thrombocytopenia

altretamine has been researched along with Thrombocytopenia in 10 studies

Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.

Thrombocytopenia: A subnormal level of BLOOD PLATELETS.

Research Excerpts

ExcerptRelevanceReference
"Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy."7.67The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984)
"Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy."3.67The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984)
"Thirty-eight women with advanced ovarian cancer were given monthly cycles of intravenous cyclophosphamide, Adriamycin (doxorubicin) and cis-platin, and oral hexamethylmelamine."1.27Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. ( Arseneau, J; Bennett, B; Greenwald, E; Kaplan, BH; Pagano, M; Vogl, SE, 1983)
"Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure."1.27Short term high density systemic therapy for metastatic breast cancer. ( Carbone, PP; Davis, TE; Kline, JC; Love, RR; Palta, M; Tormey, DC, 1985)
"Thirty-eight women with advanced ovarian cancer resistant to alkylating-agent chemotherapy were treated with a combination of hexamethylmelamine and cisplatin."1.26Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. ( Arseneau, JC; Davis, TE; Einhorn, N; Kaplan, BH; Pagano, M; Tunca, JC; Vogl, SE, 1982)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vogl, SE2
Pagano, M2
Davis, TE2
Einhorn, N1
Tunca, JC1
Kaplan, BH2
Arseneau, JC1
Edwards, CL1
Herson, J1
Gershenson, DM1
Copeland, LJ1
Wharton, JT1
Greenwald, E1
Arseneau, J1
Bennett, B1
Neijt, JP1
ten Bokkel Huinink, WW1
van der Burg, ME1
van Oosterom, AT1
Kooyman, CD1
van Houwelingen, JC1
Pinedo, HM1
Richman, CM1
Makii, MM1
Weiser, PA1
Herbst, AL1
Chahinian, AP1
Green, G1
Holland, JF1
Wilson, WL1
Ryzin, JV1
Weiss, AJ1
Frelick, RW1
Moss, SE1
Tormey, DC1
Kline, JC1
Palta, M1
Love, RR1
Carbone, PP1
Markman, M1
Abeloff, MD1
Berkman, AW1
Waterfield, WC1

Trials

3 trials available for altretamine and Thrombocytopenia

ArticleYear
A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
    Gynecologic oncology, 1983, Volume: 15, Issue:2

    Topics: Adult; Altretamine; Anemia; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophospha

1983
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1984
A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Oncology, 1975, Volume: 31, Issue:5-6

    Topics: Adenocarcinoma; Altretamine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Top

1975

Other Studies

7 other studies available for altretamine and Thrombocytopenia

ArticleYear
Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; D

1982
Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
    Cancer, 1983, Jun-01, Volume: 51, Issue:11

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis

1983
Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
    Cancer, 1984, Apr-01, Volume: 53, Issue:7

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans;

1984
The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia.
    American journal of hematology, 1984, Volume: 16, Issue:4

    Topics: Agranulocytosis; Altretamine; Cisplatin; Colony-Stimulating Factors; Cyclophosphamide; Doxorubicin;

1984
Short term high density systemic therapy for metastatic breast cancer.
    Breast cancer research and treatment, 1985, Volume: 5, Issue:2

    Topics: Altretamine; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Combined Modality Therapy; Doxorubi

1985
Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.
    Cancer treatment reports, 1985, Volume: 69, Issue:2

    Topics: Actuarial Analysis; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D

1985
Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Deoxyguanosine; Dianhydrogalactitol; Drug Evalua

1985